YL211 is another cement antibody drug conjugate that is also showing promising results and I think this establishes consistency with the target that there are multiple drugs in this space and there are actually others as well but you know there’s probably some under development but YL211 also showed efficacy in an all solid tumor dose escalation where we established the recommended phase two dose and moved on to actually dose optimization evaluating multiple doses to really confirm those escalation decisions...
YL211 is another cement antibody drug conjugate that is also showing promising results and I think this establishes consistency with the target that there are multiple drugs in this space and there are actually others as well but you know there’s probably some under development but YL211 also showed efficacy in an all solid tumor dose escalation where we established the recommended phase two dose and moved on to actually dose optimization evaluating multiple doses to really confirm those escalation decisions. And in a lung specific cohort demonstrated activity that was impressive and we’re excited for continued development in tumors.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.